Search clinical trials for: NRL001

Total 121 results

Norgine

Completed

Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different Weights

Incontinence

United Kingdom
Norgine

Completed

Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days

Fecal Incontinence

United Kingdom
Norgine

Completed

Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal Incontinence

Fecal Incontinence

United Kingdom
Norgine

Completed

Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects

Fecal Incontinence

United Kingdom
Norgine

Completed

Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers

Fecal Incontinence

Bulgaria
Norgine

Completed

Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.

Fecal Incontinence

United Kingdom
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Drug-drug Interaction and Safety Between "BR6001-1" and "BR6001-2"

Gastric or Duodenal Ulcer

Korea, Republic of
Nuvamid SA
Medpace, Inc.; Anapharm; LGD

Active, not recruiting

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

Healthy Volunteers

United States
LGD
ProRelix Services LLP

Recruiting

Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients

Sickle Cell Disease

India
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
Chipscreen Biosciences, Ltd.

Not yet recruiting

A Study of NWY001 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
AriBio Co., Ltd.

Recruiting

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

Alzheimer Disease

United States, Korea, Republic of
Achilles Therapeutics UK Limited

Terminated

Long-Term Follow-Up Study of Patients Receiving ATL001

Melanoma | Advanced Non Small Cell Lung Cancer

United Kingdom
AriBio Co., Ltd.

Completed

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

Mild to Moderate Alzheimer's Disease

United States
Renovo

Completed

Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects

Cicatrix

United Kingdom
Alector Inc.

Active, not recruiting

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Frontotemporal Dementia

Spain, United States, Portugal, United Kingdom, France, Germany, Netherlands, Belgium, Australia, Italy, Turkey, Switzerland, Argentina, Canada, Greece, Sweden
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Renal Impairment

Germany, Bulgaria
Boryung Pharmaceutical Co., Ltd

Completed

To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects

Rheumatoid Arthritis

Korea, Republic of
ExoRNA Bioscience

Recruiting

The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease

Huntington Disease

China
Promius Pharma, LLC

Terminated

Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Onychomycosis

United States, Dominican Republic
Promius Pharma, LLC

Terminated

Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Onychomycosis

United States
Zhejiang University

Not yet recruiting

Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001

Hemophilia B Without Inhibitor
Renovo

Completed

Juvista in Scar Revision Surgery of Disfiguring Scars (Revise)

Cicatrix

Spain, France, Hungary, Italy, United Kingdom, United States, Denmark, Germany, Latvia, Poland
Beijing Northland Biotech. Co., Ltd.

Completed

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

Acute Myocardial Infarction

China
Alector Inc.

Active, not recruiting

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Frontotemporal Dementia

Canada, United States, Germany, United Kingdom, Italy, Netherlands
Wuxi No. 4 People's Hospital

Not yet recruiting

Safety Study of 89Zr-NY001 PET Imaging in Patients

Solid Tumor, Adult

China
Neuraltus Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Amyotrophic Lateral Sclerosis

United States, Canada
Affiliated Hospital of Guangdong Medical University

Not yet recruiting

Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001

Hemophilia B Without Inhibitor
Beijing Northland Biotech. Co., Ltd.

Completed

Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction

Acute Myocardial Infarction

China
RenJi Hospital

Not yet recruiting

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis

Decompensated Cirrhosis
Alector Inc.
GlaxoSmithKline

Enrolling by invitation

Continuation Study for Latozinemab

Neurodegenerative Diseases

Canada, United States, Belgium, France, Spain, Portugal, Germany, Italy, Netherlands, Sweden, United Kingdom
Alector Inc.

Terminated

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Amyotrophic Lateral Sclerosis

United States
Neuraltus Pharmaceuticals, Inc.

Completed

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Neuraltus Pharmaceuticals, Inc.

Completed

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
LGD
Assistance Publique Hopitaux De Marseille; CEN Biotech; Etablissement Français...

Recruiting

Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)

Sickle Cell Disease

France
Shanghai Miracogen Inc.

Recruiting

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

Tetanus

China
Beau Nakamoto
Neuraltus Pharmaceuticals, Inc.

Terminated

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Alzheimer Disease

United States
Renovo

Completed

Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)

Cicatrix | Wound Healing | Re-epithelialization

United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

Chronic Myelogenous Leukemia

Spain, United Kingdom, Germany, Canada, Austria, France, Korea, Republic of, Greece, Singapore, Italy, Argentina, Poland, Vietnam, Malaysia, Oman, Brazil
Hangzhou Yirui Pharmaceutical Technology Co., Ltd

Not yet recruiting

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Shanghai Refreshgene Technology Co., Ltd.

Recruiting

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration

China
Novartis Pharmaceuticals

Active, not recruiting

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (AIM4CML)

Chronic Myelogenous Leukemia - Chronic Phase

United States
Renovo

Completed

Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites

Cicatrix | Wound Healing

United Kingdom
Renovo

Completed

Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)

Cicatrix | Wound Healing

United Kingdom
Institut du Cancer de Montpellier - Val d'Aurelle

Completed

Safety and Efficacity of NFL101 as Tobacco Therapy (CESTO)

Smoking

France
Kyowa Kirin Co., Ltd.

Completed

A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

Multiple Myeloma and Malignant Lymphoma

Japan
Novartis Pharmaceuticals

Recruiting

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE)

Chronic Myelogenous Leukemia - Chronic Phase

United States
ABL Bio, Inc.
National OncoVenture

Completed

This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

Advanced Solid Tumors

Korea, Republic of
Revance Therapeutics, Inc.

Completed

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States

3

Subscribe